Neurogene Inc.
NGNENasdaq
$37.31
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↑ +65.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$832.2M
Enterprise Value
$589.0M
P/E
—
P/S
—
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
-10.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$98.6M
Free Cash Flow (TTM)
-$83.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-41.5%
ROIC
—
Debt / Equity
—
Net Cash
$243.2M
Return 1Y
+65.1%
Company profile
Neoleukin Therapeutics, Inc. develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
- CEO
- Jonathan G. Drachman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- New York
- Website
- neoleukin.com
Management & directors
- Cvijic Christine MikailPresident and CFO
- Jordan JulieChief Medical Officer
- Mcminn RachelChief Executive Officer
- Cobb StuartChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
NGNE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.39↑ +28.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $925,000.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.7M | -$60.7M | -$56.5M | -$55.6M | -$82.6M | -$103.3M |
| Net income | -$33.3M | -$60.7M | -$55.2M | -$36.3M | -$75.1M | -$90.4M |
| Diluted EPS | -$0.64 | -$1.10 | -$1.04 | — | -$4.28 | -$4.24 |
| Operating cash flow | -$24.6M | -$47.6M | -$52.8M | -$51.4M | -$70.6M | -$77.2M |
| Free cash flow | -$26.8M | -$50.8M | -$55.1M | -$51.7M | -$71.4M | -$78.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -8930.3% | — |
| Net margin | — | — | — | — | -8123.7% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $925,000.00 | $0.00 | — | — | $0.00 | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$20.1M | -$22.2M | -$21.5M | -$25.9M | -$26.1M | -$23.8M | -$27.5M | -$33.3M |
| Net income | -$18.5M | -$20.2M | -$19.5M | -$22.6M | -$22.0M | -$21.0M | -$24.7M | -$30.9M |
| Diluted EPS | -$1.09 | -$1.19 | -$1.00 | -$1.08 | -$1.05 | -$0.99 | -$1.12 | -$1.39 |
| Operating cash flow | -$15.9M | -$15.6M | -$17.5M | -$20.8M | -$19.5M | -$19.5M | -$17.4M | -$26.1M |
| Free cash flow | -$16.4M | -$15.7M | -$17.6M | -$21.6M | -$19.6M | -$19.6M | -$17.6M | -$26.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -2176.6% | — | — | — | — | — | — | — |
| Net margin | -1999.1% | — | — | — | — | — | — | — |
Company news
Jul 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Cvijic Christine Mikail· President and CFO | Sale | 4,200 | $36.13 | $151,762.80 | filing |
| 2026-07-06 | Cvijic Christine Mikail· President and CFO | Sale | 600 | $36.02 | $21,612.60 | filing |
| 2026-07-02 | Cvijic Christine Mikail· President and CFO | Sale | 2,531 | $34.58 | $87,519.45 | filing |
| 2026-07-02 | Cvijic Christine Mikail· President and CFO | Sale | 1,530 | $35.23 | $53,897.31 | filing |
| 2026-07-01 | Cvijic Christine Mikail· President and CFO | Sale | 739 | $34.06 | $25,169.60 | filing |
| 2026-05-06 | Cvijic Christine Mikail· President and CFO | Sale | 4,800 | $32.44 | $155,691.84 | filing |
| 2026-05-06 | Cvijic Christine Mikail· President and CFO | Sale | 4,800 | $30.07 | $144,351.36 | filing |
| 2026-03-26 | McMinn Rachel· Chief Executive Officer | Sale | 3,352 | $22.07 | $73,995.06 | filing |
| 2026-03-26 | Cvijic Christine Mikail· President and CFO | Sale | 2,558 | $21.62 | $55,315.98 | filing |
| 2026-03-26 | Jordan Julie· Chief Medical Officer | Sale | 828 | $21.89 | $18,127.57 | filing |
| 2026-03-13 | Cobb Stuart· Chief Scientific Officer | Sale | 3,991 | $20.41 | $81,456.31 | filing |
| 2026-03-13 | Cobb Stuart· Chief Scientific Officer | Sale | 2,658 | $21.34 | $56,721.72 | filing |
| 2026-03-13 | Cvijic Christine Mikail· President and CFO | Sale | 2,387 | $20.42 | $48,748.27 | filing |
| 2026-03-13 | Cvijic Christine Mikail· President and CFO | Sale | 1,395 | $21.25 | $29,636.91 | filing |
| 2026-03-13 | Cvijic Christine Mikail· President and CFO | Sale | 263 | $22.02 | $5,791.13 | filing |
| 2026-03-13 | Cobb Stuart· Chief Scientific Officer | Sale | 148 | $22.08 | $3,267.84 | filing |
| 2026-02-27 | Cvijic Christine Mikail· President and CFO | Sale | 4,800 | $25.11 | $120,526.08 | filing |
| 2026-02-20 | Cobb Stuart· Chief Scientific Officer | Award | 16,500 | $0.00 | $0.00 | filing |
| 2026-02-20 | Jordan Julie· Chief Medical Officer | Award | 4,900 | $0.00 | $0.00 | filing |
| 2026-02-20 | Cvijic Christine Mikail· President and CFO | Award | 22,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | McMinn Rachel· Chief Executive Officer | Award | 25,900 | $0.00 | $0.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.